



1645 #39/165  
02-27-02

Dkt. 41426-D/JPW/SHS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 14 2002

TECH CENTER 1600/2900

Applicants : Ron S. Israeli, et al.  
Serial No. : 08/470,735 Group Art Unit: 1645  
Filed : June 6, 1995 Examiner: S. Gucker  
For : PROSTATE-SPECIFIC MEMBRANE ANTIGEN

1185 Avenue of the Americas  
New York, New York 10036  
November 2, 2001

Assistant Commissioner for Patents  
Washington, D.C. 20231

**COPY OF PAPERS  
ORIGINALLY FILED**

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
AND CERTIFICATION PURSUANT TO 37 C.F.R. §1.97 (e) (2)**

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following reference which is listed on the PTO-1449 form attached hereto as **Exhibit A**. A copy of this reference is attached hereto as **Exhibit 1**.

U.S. Patent No. 6,290,956 issued October September 18, 2001  
to Bander (Exhibit 1).

In addition, applicants note that the October 9, 2001 Official Gazette indicates that all references to Patent No. 6,290,956 to Neil H. Bander of Chappaqua, N.Y. for TREATMENT AND DIAGNOSIS OF PROSTATE CANCER appearing in the Official Gazette of September 18, 2001 should be deleted since no patent was granted.

In compliance with 37 C.F.R. §1.97(e)(2), no item of information contained in this supplemental information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the

RECEIVED

FEB 6 2002

TECH CENTER 1600/2900


Applicants : Ron S. Israeli, et al.  
Serial No. : 08/470,735  
Filed : June 6, 1995  
Page 2

person signing the certification after making reasonable inquiry, no item of information contained in the supplemental information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to filing this supplemental information disclosure statement.


If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

Pursuant to 37 C.F.R. §1.97(c)(1), no fee is deemed necessary in connection with the filing of this supplemental information disclosure statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

 1-2-01  
John P. White  
Reg. No. 28,678  
Spencer H. Schneider  
Reg. No. 45,923

Date

John P. White  
Registration No. 28,678  
Spencer H. Schneider  
Registration No. 45,923  
Attorneys for Applicant(s)  
Cooper & Dunham, LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400